Eli Lilly and Novo Nordisk are increasingly using manufacturing capacity as a strategic advantage in the obesity-drug market. Eli Lilly has committed tens of billions of dollars to expand its U.S. manufacturing footprint across multiple technologies, including active pharmaceutical ingredients, injectable medicines, and advanced therapies, aiming to support current products like Mounjaro and Zepbound as well as future pipeline assets. Novo Nordisk has invested nearly $6 billion over three decades to expand its Clayton, North Carolina campus and strengthen fill-finish capabilities through the acquisition of former Catalent facilities, leveraging its decades of peptide manufacturing expertise and a more geographically diversified production network. The companies face different risks: Eli Lilly’s aggressive investment could become a fixed cost if supply catches up with demand, while Novo Nordisk must ensure its capacity expands fast enough to avoid shortages that have previously constrained supply. The outcome of this manufacturing race may determine which company dominates the next decade of obesity treatment.
